Hepatic stem cells: A viable approach for the treatment of liver cirrhosis  

作　　者：Md Aejaz Habeeb Sandeep Kumar Vishwakarma Avinash Bardia Aleem Ahmed Khan 

机构地区：[1]Center for Liver Research and Diagnostics, Deccan College of Medical Sciences

出　　处：《World Journal of Stem Cells》2015年第5期860-865,共6页世界干细胞杂志（英文版）（电子版）

摘　　要：Liver cirrhosis is characterized by distortion of liver architecture, necrosis of hepatocytes and regenerative nodules formation leading to cirrhosis. Various types of cell sources have been used for the management and treatment of decompensated liver cirrhosis.Knowledge of stem cells has offered a new dimension for regenerative therapy and has been considered as one of the potential adjuvant treatment modality in patients with end stage liver diseases(ESLD). Human fetal hepatic progenitor cells are less immunogenic than adult ones. They are highly propagative and challenging to cryopreservation. In our earlier studies we have demonstrated that fetuses at 10-18 wk of gestation age contain a large number of actively dividing hepatic stem and progenitor cells which possess bipotent nature having potential to differentiate into bile duct cells and mature hepatocytes. Hepatic stem cell therapy for the treatment of ESLD is in their early stage of the translation. The emerging technology of decellularization and recellularization might offer a significant platform for developing bioengineered personalized livers to come over the scarcity of desired number of donor organs for the treatment of ESLD. Despite these significant advancements long-term tracking of stem cells in human is the most important subject nowadays in order to answer several unsettles issues regarding the route of delivery, the choice of stem cell type(s), the cell number and the timepoint of cell delivery for the treatment in a chronic setting. Answering to these questions will further contribute to the development of safer, noninvasive, and repeatable imaging modalities that could discover better cell therapeutic approaches from bench to bedside. Combinatorial approach of decellularization and nanotechnology could pave a way towards the better understanding in determination of cell fate posttransplantation.Liver cirrhosis is characterized by distortion of liverarchitecture, necrosis of hepatocytes and regenerativenodules formation leading to cirrhosis. Various typesof cell sources have been used for the managementand treatment of decompensated liver cirrhosis.Knowledge of stem cells has offered a new dimensionfor regenerative therapy and has been considered asone of the potential adjuvant treatment modality inpatients with end stage liver diseases （ESLD）. Humanfetal hepatic progenitor cells are less immunogenic thanadult ones. They are highly propagative and challengingto cryopreservation. In our earlier studies we havedemonstrated that fetuses at 10-18 wk of gestationage contain a large number of actively dividinghepatic stem and progenitor cells which possess bipotentnature having potential to differentiate intobile duct cells and mature hepatocytes. Hepatic stemcell therapy for the treatment of ESLD is in their earlystage of the translation. The emerging technologyof decellularization and recellularization might offera significant platform for developing bioengineeredpersonalized livers to come over the scarcity of desirednumber of donor organs for the treatment of ESLD.Despite these significant advancements long-termtracking of stem cells in human is the most importantsubject nowadays in order to answer several unsettlesissues regarding the route of delivery, the choiceof stem cell type（s）, the cell number and the timepointof cell delivery for the treatment in a chronicsetting. Answering to these questions will furthercontribute to the development of safer, noninvasive,and repeatable imaging modalities that could discoverbetter cell therapeutic approaches from bench to bedside.Combinatorial approach of decellularization andnanotechnology could pave a way towards the betterunderstanding in determination of cell fate posttransplantation.

关 键 词：HEPATIC STEM cells BIOENGINEERING LIVERCIRRHOSIS LABELING and tracking 

分 类 号：R575.2[医药卫生—消化系统]